Product Description
Doxapram produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. It is thought to stimulate the carotid body by inhibiting certain potassium channels. Doxapram is a member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Doxapram)
Mechanisms of Action: Potassium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Belgium | Canada | China | Egypt | France | Germany | Greece | India | Ireland | Italy | Japan | Korea | Malta | New Zealand | Romania | Taiwan | Turkey | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Erasmus Medical Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Apnea|Bradycardia|Respiratory Insufficiency
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DOXA Trial | P3 |
Active, not recruiting |
Respiratory Insufficiency|Bradycardia|Apnea |
2029-04-21 |
|
| QEV-817-101 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-12-01 |